| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Patient Education as Topic | 18 | 2020 | 444 | 4.940 |
Why?
|
| Asthma | 31 | 2023 | 756 | 4.210 |
Why?
|
| Lung Diseases | 9 | 2021 | 384 | 2.410 |
Why?
|
| Cystic Fibrosis | 15 | 2017 | 258 | 2.030 |
Why?
|
| Pulmonary Embolism | 4 | 2021 | 171 | 1.710 |
Why?
|
| Hypertension, Pulmonary | 4 | 2021 | 439 | 1.560 |
Why?
|
| Pandemics | 5 | 2021 | 1112 | 1.440 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 360 | 1.420 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 376 | 1.410 |
Why?
|
| Practice Guidelines as Topic | 5 | 2021 | 1269 | 1.330 |
Why?
|
| Betacoronavirus | 2 | 2020 | 289 | 1.070 |
Why?
|
| Pamphlets | 2 | 2016 | 23 | 1.060 |
Why?
|
| Self Care | 13 | 2016 | 215 | 1.030 |
Why?
|
| Allergens | 4 | 2022 | 252 | 0.890 |
Why?
|
| Humans | 96 | 2023 | 125287 | 0.870 |
Why?
|
| Chronic Disease | 5 | 2021 | 1189 | 0.840 |
Why?
|
| Lung Diseases, Interstitial | 3 | 2021 | 150 | 0.770 |
Why?
|
| Neuroendocrine Cells | 1 | 2021 | 10 | 0.750 |
Why?
|
| Occupational Exposure | 2 | 2022 | 128 | 0.750 |
Why?
|
| Exercise Tolerance | 1 | 2022 | 84 | 0.740 |
Why?
|
| Hyperplasia | 1 | 2021 | 200 | 0.720 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 2019 | 91 | 0.720 |
Why?
|
| Socialization | 1 | 2021 | 16 | 0.710 |
Why?
|
| Exercise Test | 1 | 2022 | 254 | 0.710 |
Why?
|
| Tobacco Smoke Pollution | 6 | 2013 | 77 | 0.700 |
Why?
|
| Lung | 7 | 2019 | 1494 | 0.690 |
Why?
|
| Forced Expiratory Volume | 9 | 2022 | 171 | 0.680 |
Why?
|
| Masks | 1 | 2020 | 38 | 0.680 |
Why?
|
| Pneumothorax | 1 | 2020 | 76 | 0.660 |
Why?
|
| Vaccines, Conjugate | 1 | 2020 | 78 | 0.660 |
Why?
|
| Health Equity | 1 | 2021 | 58 | 0.660 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 84 | 0.650 |
Why?
|
| Immunization | 1 | 2021 | 307 | 0.640 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 1 | 2019 | 16 | 0.640 |
Why?
|
| Societies, Medical | 3 | 2021 | 700 | 0.640 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2020 | 83 | 0.640 |
Why?
|
| Communicable Disease Control | 1 | 2021 | 138 | 0.640 |
Why?
|
| Oral Hygiene | 1 | 2019 | 9 | 0.630 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2022 | 319 | 0.620 |
Why?
|
| Central Venous Catheters | 1 | 2019 | 39 | 0.620 |
Why?
|
| Sleep Wake Disorders | 3 | 2016 | 168 | 0.620 |
Why?
|
| Bronchodilator Agents | 3 | 2019 | 151 | 0.620 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2019 | 57 | 0.620 |
Why?
|
| Bronchitis | 1 | 2018 | 34 | 0.610 |
Why?
|
| Communicable Diseases | 1 | 2021 | 161 | 0.610 |
Why?
|
| Nonprescription Drugs | 1 | 2019 | 50 | 0.600 |
Why?
|
| Pneumococcal Vaccines | 1 | 2020 | 169 | 0.600 |
Why?
|
| Prescription Drugs | 1 | 2019 | 54 | 0.590 |
Why?
|
| Respiratory Care Units | 1 | 2017 | 1 | 0.580 |
Why?
|
| Catheterization, Central Venous | 1 | 2019 | 128 | 0.580 |
Why?
|
| Antihypertensive Agents | 1 | 2021 | 415 | 0.570 |
Why?
|
| Catheter-Related Infections | 1 | 2019 | 127 | 0.560 |
Why?
|
| Equipment and Supplies | 1 | 2017 | 25 | 0.560 |
Why?
|
| Vaccination | 2 | 2021 | 961 | 0.530 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2017 | 54 | 0.530 |
Why?
|
| Adolescent Development | 1 | 2017 | 25 | 0.530 |
Why?
|
| Ventilators, Mechanical | 1 | 2016 | 40 | 0.530 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2016 | 13 | 0.530 |
Why?
|
| Child | 43 | 2023 | 24571 | 0.530 |
Why?
|
| Puberty | 1 | 2017 | 95 | 0.520 |
Why?
|
| Venous Thrombosis | 1 | 2018 | 166 | 0.510 |
Why?
|
| Disaster Planning | 1 | 2016 | 63 | 0.510 |
Why?
|
| Vaccines | 1 | 2021 | 366 | 0.510 |
Why?
|
| Lung Transplantation | 2 | 2017 | 322 | 0.500 |
Why?
|
| Tonsillectomy | 1 | 2017 | 99 | 0.490 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 195 | 0.490 |
Why?
|
| Soybean Proteins | 1 | 2015 | 17 | 0.480 |
Why?
|
| Influenza, Human | 2 | 2020 | 660 | 0.480 |
Why?
|
| Health Literacy | 1 | 2016 | 80 | 0.480 |
Why?
|
| Nutrition Therapy | 1 | 2015 | 12 | 0.480 |
Why?
|
| Isoflavones | 1 | 2015 | 44 | 0.470 |
Why?
|
| Bronchial Provocation Tests | 1 | 2014 | 14 | 0.450 |
Why?
|
| Methacholine Chloride | 1 | 2014 | 21 | 0.450 |
Why?
|
| Plant Extracts | 1 | 2015 | 118 | 0.440 |
Why?
|
| Androstadienes | 1 | 2014 | 50 | 0.440 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2017 | 206 | 0.430 |
Why?
|
| Respiration, Artificial | 1 | 2016 | 473 | 0.430 |
Why?
|
| Sleep | 1 | 2017 | 346 | 0.430 |
Why?
|
| Smoking Cessation | 3 | 2004 | 198 | 0.410 |
Why?
|
| Critical Care | 1 | 2017 | 657 | 0.390 |
Why?
|
| Respiratory Tract Infections | 4 | 2018 | 274 | 0.380 |
Why?
|
| United States | 13 | 2021 | 10875 | 0.370 |
Why?
|
| Dietary Supplements | 1 | 2015 | 471 | 0.370 |
Why?
|
| Smoking Prevention | 2 | 2004 | 37 | 0.350 |
Why?
|
| Adolescent | 28 | 2023 | 19409 | 0.340 |
Why?
|
| Renal Dialysis | 1 | 2017 | 846 | 0.330 |
Why?
|
| Anticoagulants | 3 | 2019 | 577 | 0.330 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 875 | 0.310 |
Why?
|
| Physician's Role | 2 | 2004 | 168 | 0.310 |
Why?
|
| Emergency Service, Hospital | 3 | 2022 | 1070 | 0.300 |
Why?
|
| Lansoprazole | 3 | 2015 | 26 | 0.290 |
Why?
|
| Irritants | 3 | 2022 | 7 | 0.290 |
Why?
|
| Gastroesophageal Reflux | 4 | 2015 | 327 | 0.290 |
Why?
|
| Administration, Inhalation | 4 | 2019 | 180 | 0.290 |
Why?
|
| Environmental Exposure | 4 | 2003 | 218 | 0.280 |
Why?
|
| Cost of Illness | 1 | 2009 | 253 | 0.280 |
Why?
|
| Respiratory Sounds | 4 | 2016 | 70 | 0.280 |
Why?
|
| Male | 37 | 2021 | 61544 | 0.270 |
Why?
|
| Female | 39 | 2021 | 66802 | 0.270 |
Why?
|
| Polysomnography | 2 | 2017 | 146 | 0.260 |
Why?
|
| Infant, Newborn | 10 | 2021 | 8253 | 0.250 |
Why?
|
| Respiratory Function Tests | 6 | 2017 | 199 | 0.250 |
Why?
|
| Medicine in Literature | 1 | 2005 | 3 | 0.250 |
Why?
|
| Expeditions | 1 | 2005 | 5 | 0.250 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2015 | 20 | 0.240 |
Why?
|
| Famous Persons | 1 | 2005 | 15 | 0.240 |
Why?
|
| Military Medicine | 1 | 2005 | 49 | 0.240 |
Why?
|
| Long-Term Care | 2 | 2019 | 71 | 0.230 |
Why?
|
| Quality of Life | 7 | 2023 | 1946 | 0.230 |
Why?
|
| Healthcare Disparities | 1 | 2009 | 431 | 0.230 |
Why?
|
| Infant Welfare | 1 | 2003 | 28 | 0.220 |
Why?
|
| Health Services Accessibility | 1 | 2009 | 602 | 0.220 |
Why?
|
| Infant | 11 | 2021 | 12570 | 0.220 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2019 | 112 | 0.210 |
Why?
|
| Glucocorticoids | 2 | 2015 | 384 | 0.210 |
Why?
|
| Schools | 3 | 2006 | 219 | 0.200 |
Why?
|
| Dust | 1 | 2022 | 17 | 0.200 |
Why?
|
| Adult | 19 | 2023 | 29579 | 0.200 |
Why?
|
| Child, Preschool | 14 | 2021 | 14114 | 0.190 |
Why?
|
| Symptom Assessment | 1 | 2020 | 101 | 0.170 |
Why?
|
| Physical Therapy Modalities | 1 | 2000 | 52 | 0.170 |
Why?
|
| Program Evaluation | 5 | 2006 | 440 | 0.170 |
Why?
|
| Severity of Illness Index | 9 | 2012 | 2907 | 0.160 |
Why?
|
| Medicaid | 1 | 2022 | 240 | 0.160 |
Why?
|
| Ibuprofen | 2 | 1999 | 40 | 0.160 |
Why?
|
| Cough | 2 | 2018 | 94 | 0.160 |
Why?
|
| Sleep Hygiene | 1 | 2019 | 9 | 0.160 |
Why?
|
| Central Nervous System Depressants | 1 | 2019 | 21 | 0.160 |
Why?
|
| Phototherapy | 1 | 2019 | 35 | 0.160 |
Why?
|
| Melatonin | 1 | 2019 | 27 | 0.160 |
Why?
|
| Embolectomy | 1 | 2019 | 7 | 0.160 |
Why?
|
| Gingival Diseases | 1 | 2019 | 2 | 0.160 |
Why?
|
| Dental Caries | 1 | 2019 | 10 | 0.160 |
Why?
|
| Respiratory Therapy | 1 | 1998 | 21 | 0.150 |
Why?
|
| Oxygen | 1 | 2022 | 556 | 0.150 |
Why?
|
| Reproducibility of Results | 6 | 2014 | 2901 | 0.150 |
Why?
|
| Double-Blind Method | 5 | 2015 | 1634 | 0.150 |
Why?
|
| Air Pollutants | 1 | 1999 | 102 | 0.150 |
Why?
|
| Obesity | 2 | 2014 | 2250 | 0.150 |
Why?
|
| Aftercare | 1 | 2019 | 149 | 0.140 |
Why?
|
| Counseling | 4 | 2004 | 220 | 0.140 |
Why?
|
| Walk Test | 1 | 2017 | 24 | 0.140 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2021 | 374 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 1999 | 304 | 0.140 |
Why?
|
| Early Medical Intervention | 1 | 2017 | 30 | 0.140 |
Why?
|
| Problem-Based Learning | 1 | 1998 | 72 | 0.140 |
Why?
|
| Middle Aged | 11 | 2018 | 26788 | 0.140 |
Why?
|
| Health Status Indicators | 2 | 1994 | 124 | 0.140 |
Why?
|
| Vital Capacity | 5 | 2014 | 76 | 0.140 |
Why?
|
| Attitude of Health Personnel | 3 | 1999 | 674 | 0.130 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 152 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2000 | 475 | 0.130 |
Why?
|
| Cross-Sectional Studies | 7 | 2010 | 3428 | 0.130 |
Why?
|
| Algorithms | 2 | 2022 | 1631 | 0.130 |
Why?
|
| Surveys and Questionnaires | 8 | 2012 | 3741 | 0.130 |
Why?
|
| Comprehension | 1 | 2016 | 74 | 0.130 |
Why?
|
| Education, Medical, Undergraduate | 1 | 1998 | 164 | 0.130 |
Why?
|
| Computer-Assisted Instruction | 3 | 2001 | 51 | 0.120 |
Why?
|
| Health Behavior | 4 | 2023 | 383 | 0.120 |
Why?
|
| Depression | 1 | 2014 | 1236 | 0.120 |
Why?
|
| Bacterial Infections | 1 | 2018 | 306 | 0.120 |
Why?
|
| Emergencies | 1 | 2016 | 172 | 0.120 |
Why?
|
| Genistein | 1 | 2015 | 39 | 0.120 |
Why?
|
| Health Services Needs and Demand | 1 | 2016 | 174 | 0.120 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 1898 | 0.120 |
Why?
|
| Air Pollution, Indoor | 3 | 2002 | 31 | 0.120 |
Why?
|
| Phytotherapy | 1 | 2015 | 48 | 0.120 |
Why?
|
| Leprosy, Tuberculoid | 1 | 2014 | 7 | 0.120 |
Why?
|
| Molluscum Contagiosum | 1 | 2014 | 11 | 0.110 |
Why?
|
| Epidermodysplasia Verruciformis | 1 | 2014 | 13 | 0.110 |
Why?
|
| Cross-Over Studies | 2 | 2014 | 313 | 0.110 |
Why?
|
| Mucous Membrane | 1 | 2014 | 89 | 0.110 |
Why?
|
| Fluticasone | 1 | 2014 | 15 | 0.110 |
Why?
|
| Granuloma | 1 | 2014 | 68 | 0.110 |
Why?
|
| Health Promotion | 1 | 1997 | 388 | 0.110 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2014 | 106 | 0.110 |
Why?
|
| Hospitalization | 1 | 2022 | 1786 | 0.110 |
Why?
|
| Students, Medical | 1 | 1998 | 354 | 0.110 |
Why?
|
| Young Adult | 3 | 2023 | 9058 | 0.110 |
Why?
|
| Internet | 1 | 2016 | 376 | 0.110 |
Why?
|
| Cardiac Catheterization | 1 | 2017 | 634 | 0.110 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2006 | 172 | 0.100 |
Why?
|
| Physicians | 2 | 1999 | 587 | 0.100 |
Why?
|
| Leukotriene Antagonists | 2 | 2009 | 17 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2009 | 850 | 0.100 |
Why?
|
| Microfilament Proteins | 1 | 2014 | 276 | 0.100 |
Why?
|
| Disease Progression | 3 | 2014 | 2081 | 0.100 |
Why?
|
| Acetates | 2 | 2009 | 73 | 0.100 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2012 | 31 | 0.100 |
Why?
|
| Echocardiography | 1 | 2017 | 1059 | 0.100 |
Why?
|
| Electrocardiography | 1 | 2017 | 978 | 0.100 |
Why?
|
| Killer Cells, Natural | 1 | 2014 | 327 | 0.100 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 2174 | 0.100 |
Why?
|
| Quinolines | 2 | 2009 | 103 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 471 | 0.090 |
Why?
|
| B-Lymphocytes | 1 | 2014 | 533 | 0.090 |
Why?
|
| Critical Illness | 1 | 2016 | 601 | 0.090 |
Why?
|
| Skin | 1 | 2014 | 521 | 0.090 |
Why?
|
| Comorbidity | 1 | 2016 | 1528 | 0.090 |
Why?
|
| Proton Pump Inhibitors | 3 | 2015 | 277 | 0.090 |
Why?
|
| Risk Factors | 3 | 2018 | 10283 | 0.090 |
Why?
|
| Prognosis | 2 | 2017 | 4678 | 0.090 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 296 | 0.090 |
Why?
|
| Evaluation Studies as Topic | 4 | 2000 | 257 | 0.090 |
Why?
|
| Pilot Projects | 3 | 2006 | 1397 | 0.090 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2013 | 207 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1691 | 0.080 |
Why?
|
| Models, Educational | 3 | 2006 | 74 | 0.080 |
Why?
|
| Diagnostic Errors | 1 | 2014 | 334 | 0.080 |
Why?
|
| Sex Factors | 2 | 2012 | 1275 | 0.080 |
Why?
|
| Respiratory Tract Diseases | 1 | 2010 | 75 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 587 | 0.080 |
Why?
|
| Probability | 1 | 2009 | 318 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2002 | 292 | 0.070 |
Why?
|
| Logistic Models | 2 | 2013 | 1803 | 0.070 |
Why?
|
| Factor Analysis, Statistical | 3 | 2000 | 234 | 0.070 |
Why?
|
| Aged | 2 | 2018 | 19700 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2015 | 3439 | 0.070 |
Why?
|
| Pediatrics | 1 | 1997 | 1157 | 0.070 |
Why?
|
| Polymorphism, Genetic | 2 | 2015 | 818 | 0.070 |
Why?
|
| Health Education | 2 | 2006 | 218 | 0.070 |
Why?
|
| Linear Models | 1 | 2009 | 686 | 0.070 |
Why?
|
| Mass Screening | 2 | 2007 | 779 | 0.070 |
Why?
|
| Age Factors | 2 | 2009 | 2819 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 6536 | 0.070 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2006 | 19 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2022 | 16345 | 0.070 |
Why?
|
| Computer Systems | 1 | 2006 | 37 | 0.070 |
Why?
|
| Pain | 1 | 2010 | 449 | 0.070 |
Why?
|
| Case Management | 1 | 2006 | 20 | 0.070 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2007 | 190 | 0.070 |
Why?
|
| Socioeconomic Factors | 1 | 2009 | 860 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2012 | 1117 | 0.060 |
Why?
|
| Anemia, Sickle Cell | 1 | 2010 | 331 | 0.060 |
Why?
|
| Patient Acuity | 1 | 2015 | 66 | 0.060 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 1 | 2005 | 5 | 0.060 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2005 | 9 | 0.060 |
Why?
|
| Child Health Services | 1 | 2006 | 86 | 0.060 |
Why?
|
| Regression Analysis | 2 | 1999 | 775 | 0.060 |
Why?
|
| Urban Population | 4 | 2006 | 227 | 0.060 |
Why?
|
| History, 19th Century | 1 | 2005 | 117 | 0.060 |
Why?
|
| Treatment Outcome | 5 | 2015 | 12293 | 0.060 |
Why?
|
| Antigens | 1 | 2005 | 156 | 0.060 |
Why?
|
| Expert Systems | 1 | 2004 | 15 | 0.060 |
Why?
|
| Statistics as Topic | 1 | 2015 | 257 | 0.060 |
Why?
|
| Emergency Medicine | 1 | 2006 | 150 | 0.060 |
Why?
|
| Drug Monitoring | 1 | 2015 | 171 | 0.050 |
Why?
|
| Thinness | 1 | 2014 | 70 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2014 | 1562 | 0.050 |
Why?
|
| Behavior Therapy | 1 | 2006 | 256 | 0.050 |
Why?
|
| Psychometrics | 2 | 2012 | 672 | 0.050 |
Why?
|
| Child Day Care Centers | 1 | 2002 | 26 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2006 | 654 | 0.050 |
Why?
|
| Spirometry | 2 | 2012 | 73 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2005 | 367 | 0.050 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2002 | 94 | 0.050 |
Why?
|
| School Health Services | 2 | 2006 | 99 | 0.050 |
Why?
|
| High-Frequency Ventilation | 1 | 2001 | 17 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2002 | 188 | 0.050 |
Why?
|
| Positive-Pressure Respiration | 1 | 2001 | 84 | 0.050 |
Why?
|
| Overweight | 1 | 2014 | 363 | 0.050 |
Why?
|
| Monitoring, Physiologic | 2 | 2009 | 377 | 0.050 |
Why?
|
| Smoking | 2 | 1997 | 1047 | 0.040 |
Why?
|
| Environmental Monitoring | 2 | 2002 | 65 | 0.040 |
Why?
|
| Self Report | 1 | 2023 | 515 | 0.040 |
Why?
|
| Ventilation | 1 | 1999 | 5 | 0.040 |
Why?
|
| Texas | 4 | 2006 | 3582 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2015 | 6160 | 0.040 |
Why?
|
| Pregnancy | 3 | 2003 | 7216 | 0.040 |
Why?
|
| Influenza Vaccines | 1 | 2004 | 479 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 1999 | 113 | 0.040 |
Why?
|
| Program Development | 1 | 2000 | 185 | 0.040 |
Why?
|
| Sulfides | 2 | 2009 | 21 | 0.040 |
Why?
|
| Mutation | 2 | 2014 | 5900 | 0.040 |
Why?
|
| Cyclopropanes | 2 | 2009 | 67 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2023 | 1175 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 1999 | 285 | 0.040 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 1997 | 13 | 0.030 |
Why?
|
| Psychology, Adolescent | 1 | 1997 | 32 | 0.030 |
Why?
|
| Psychology, Child | 1 | 1997 | 43 | 0.030 |
Why?
|
| Time Factors | 2 | 2015 | 6311 | 0.030 |
Why?
|
| Community Participation | 1 | 1997 | 44 | 0.030 |
Why?
|
| Societies | 1 | 2016 | 25 | 0.030 |
Why?
|
| Telephone | 1 | 1997 | 110 | 0.030 |
Why?
|
| Salicylamides | 1 | 1975 | 1 | 0.030 |
Why?
|
| Bronchial Hyperreactivity | 1 | 1996 | 38 | 0.030 |
Why?
|
| Digitoxin | 1 | 1975 | 11 | 0.030 |
Why?
|
| Disinfectants | 1 | 1975 | 25 | 0.030 |
Why?
|
| Phenotype | 1 | 2015 | 4268 | 0.030 |
Why?
|
| Nicotine | 1 | 1997 | 143 | 0.030 |
Why?
|
| Risk-Taking | 1 | 1996 | 96 | 0.030 |
Why?
|
| Microsomes, Liver | 1 | 1975 | 91 | 0.030 |
Why?
|
| Obstetrics | 1 | 1998 | 238 | 0.030 |
Why?
|
| Prenatal Care | 1 | 1998 | 348 | 0.030 |
Why?
|
| Workplace | 1 | 1996 | 70 | 0.030 |
Why?
|
| Educational Status | 2 | 2006 | 275 | 0.030 |
Why?
|
| Health Status | 2 | 1994 | 376 | 0.030 |
Why?
|
| Acute Disease | 2 | 2010 | 1095 | 0.030 |
Why?
|
| Forced Expiratory Flow Rates | 1 | 1994 | 7 | 0.030 |
Why?
|
| Caregivers | 2 | 1997 | 578 | 0.030 |
Why?
|
| Telomere Shortening | 1 | 2014 | 33 | 0.030 |
Why?
|
| Airway Obstruction | 1 | 1996 | 165 | 0.030 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1996 | 229 | 0.030 |
Why?
|
| Siblings | 1 | 2014 | 186 | 0.030 |
Why?
|
| Software | 1 | 1998 | 687 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2009 | 443 | 0.030 |
Why?
|
| Airway Resistance | 1 | 2013 | 36 | 0.030 |
Why?
|
| Models, Psychological | 1 | 1994 | 138 | 0.030 |
Why?
|
| Plethysmography | 1 | 2013 | 35 | 0.030 |
Why?
|
| Leukotrienes | 1 | 2013 | 7 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2014 | 190 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2013 | 49 | 0.030 |
Why?
|
| Observer Variation | 1 | 1994 | 300 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2009 | 681 | 0.030 |
Why?
|
| Goals | 1 | 1993 | 128 | 0.030 |
Why?
|
| Guideline Adherence | 2 | 2006 | 373 | 0.030 |
Why?
|
| Recurrence | 1 | 2016 | 1392 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 1993 | 122 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 809 | 0.020 |
Why?
|
| Heterozygote | 1 | 2014 | 672 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 631 | 0.020 |
Why?
|
| Disease Management | 1 | 2016 | 531 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 1994 | 405 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2012 | 275 | 0.020 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 1992 | 79 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 5169 | 0.020 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 1984 | 217 | 0.020 |
Why?
|
| Primary Prevention | 1 | 1992 | 172 | 0.020 |
Why?
|
| Ecology | 1 | 1970 | 12 | 0.020 |
Why?
|
| Spiders | 1 | 1970 | 6 | 0.020 |
Why?
|
| Ants | 1 | 1970 | 8 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2012 | 4835 | 0.020 |
Why?
|
| Patient Compliance | 1 | 1993 | 473 | 0.020 |
Why?
|
| Prevalence | 2 | 2010 | 2459 | 0.020 |
Why?
|
| Esomeprazole | 1 | 2009 | 32 | 0.020 |
Why?
|
| Anti-Ulcer Agents | 1 | 2009 | 115 | 0.020 |
Why?
|
| Chest Pain | 1 | 2010 | 129 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1330 | 0.020 |
Why?
|
| Health Surveys | 1 | 2010 | 245 | 0.020 |
Why?
|
| Lung Neoplasms | 2 | 1996 | 1654 | 0.020 |
Why?
|
| Theophylline | 1 | 2008 | 29 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 2058 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2007 | 89 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2007 | 144 | 0.020 |
Why?
|
| Absenteeism | 1 | 2006 | 20 | 0.020 |
Why?
|
| Tyrosine Transaminase | 1 | 1975 | 12 | 0.020 |
Why?
|
| Chromatography, Thin Layer | 2 | 1975 | 46 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2006 | 283 | 0.020 |
Why?
|
| Environment | 1 | 2006 | 144 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2006 | 371 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2006 | 141 | 0.010 |
Why?
|
| Mucin-1 | 1 | 2005 | 35 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1975 | 216 | 0.010 |
Why?
|
| Mucins | 1 | 2005 | 75 | 0.010 |
Why?
|
| Parent-Child Relations | 1 | 2006 | 247 | 0.010 |
Why?
|
| Knowledge | 1 | 2004 | 47 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2006 | 759 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 3175 | 0.010 |
Why?
|
| Placebos | 1 | 2004 | 241 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2006 | 363 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2004 | 266 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2006 | 429 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 822 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 1977 | 479 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2005 | 384 | 0.010 |
Why?
|
| Maximum Allowable Concentration | 1 | 2002 | 7 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 2004 | 439 | 0.010 |
Why?
|
| Floors and Floorcoverings | 1 | 2002 | 3 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1977 | 939 | 0.010 |
Why?
|
| Epidemiological Monitoring | 1 | 2002 | 59 | 0.010 |
Why?
|
| Computer Graphics | 1 | 2001 | 38 | 0.010 |
Why?
|
| User-Computer Interface | 1 | 2001 | 155 | 0.010 |
Why?
|
| Liver | 1 | 1975 | 1749 | 0.010 |
Why?
|
| Motivation | 1 | 2001 | 319 | 0.010 |
Why?
|
| Drug Utilization | 1 | 1999 | 161 | 0.010 |
Why?
|
| Necrosis | 1 | 1997 | 209 | 0.010 |
Why?
|
| Thoracotomy | 1 | 1997 | 109 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 1997 | 163 | 0.010 |
Why?
|
| Salicylanilides | 1 | 1975 | 1 | 0.010 |
Why?
|
| Methods | 1 | 1975 | 149 | 0.010 |
Why?
|
| Digitoxigenin | 1 | 1975 | 10 | 0.010 |
Why?
|
| Pneumonectomy | 1 | 1997 | 143 | 0.010 |
Why?
|
| Hydroxylation | 1 | 1975 | 49 | 0.010 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1975 | 88 | 0.010 |
Why?
|
| NADP | 1 | 1975 | 52 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1997 | 1018 | 0.010 |
Why?
|
| Rabbits | 1 | 1975 | 717 | 0.010 |
Why?
|
| Cefoxitin | 1 | 1984 | 5 | 0.010 |
Why?
|
| Erythromycin | 1 | 1984 | 20 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1975 | 971 | 0.010 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 1984 | 46 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1984 | 194 | 0.010 |
Why?
|
| Self Concept | 1 | 1994 | 155 | 0.010 |
Why?
|
| Animals | 4 | 1975 | 34299 | 0.010 |
Why?
|
| Family | 1 | 1994 | 567 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 1994 | 449 | 0.010 |
Why?
|
| Metamorphosis, Biological | 1 | 1970 | 7 | 0.010 |
Why?
|
| Pigmentation | 1 | 1970 | 34 | 0.010 |
Why?
|
| Adaptation, Biological | 1 | 1970 | 32 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1984 | 1174 | 0.010 |
Why?
|
| Extremities | 1 | 1970 | 82 | 0.010 |
Why?
|
| Abdomen | 1 | 1970 | 126 | 0.010 |
Why?
|
| Patient Care Team | 1 | 1993 | 545 | 0.000 |
Why?
|
| Biological Evolution | 1 | 1970 | 227 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1997 | 2090 | 0.000 |
Why?
|
| Rats | 1 | 1975 | 3726 | 0.000 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1984 | 669 | 0.000 |
Why?
|
| Sex Characteristics | 1 | 1970 | 314 | 0.000 |
Why?
|
| Nephrosis | 1 | 1977 | 4 | 0.000 |
Why?
|
| Adrenal Gland Diseases | 1 | 1977 | 13 | 0.000 |
Why?
|
| Polycystic Kidney Diseases | 1 | 1977 | 30 | 0.000 |
Why?
|
| Hydronephrosis | 1 | 1977 | 35 | 0.000 |
Why?
|
| Kidney Diseases, Cystic | 1 | 1977 | 39 | 0.000 |
Why?
|
| Avian Leukosis Virus | 1 | 1975 | 14 | 0.000 |
Why?
|
| Hematoma | 1 | 1977 | 91 | 0.000 |
Why?
|
| Enzyme Induction | 1 | 1975 | 104 | 0.000 |
Why?
|
| Abscess | 1 | 1977 | 137 | 0.000 |
Why?
|
| Glucagon | 1 | 1975 | 184 | 0.000 |
Why?
|
| Wilms Tumor | 1 | 1977 | 117 | 0.000 |
Why?
|
| Chickens | 1 | 1975 | 636 | 0.000 |
Why?
|
| Models, Biological | 1 | 1970 | 1465 | 0.000 |
Why?
|
| Neoplasm Transplantation | 1 | 1975 | 383 | 0.000 |
Why?
|
| Transplantation, Homologous | 1 | 1975 | 620 | 0.000 |
Why?
|
| Dexamethasone | 1 | 1975 | 274 | 0.000 |
Why?
|
| Circadian Rhythm | 1 | 1975 | 274 | 0.000 |
Why?
|
| Kidney Neoplasms | 1 | 1977 | 440 | 0.000 |
Why?
|
| Cell Line | 1 | 1975 | 2754 | 0.000 |
Why?
|
| Adenocarcinoma | 1 | 1977 | 1025 | 0.000 |
Why?
|